PREDICTION OF CLINICAL COURSE AND RECURRENCE OF HUMAN OVARIAN CANCER BY SEVERAL SERUM TUMOR MARKERS
スポンサーリンク
概要
- 論文の詳細を見る
進行期卵巣癌43名の患者において7種の血清腫瘍マーカーを術前術後および化学療法の経過中に測定した。これら血清腫瘍マーカーの術前の陽性率はCA 125で94.4%, β_2-microglobulin (β_2M) で62.2%, 血沈 (ESR) で51.3%, α-hydroxybutyrate dehydrogenase (HBD) で54.8%, lactate dehydrogenase (LDH) で46.5%であった。腫瘍が完全に摘出された症例ではLDH, LDH-4およびHBDは術後有意に減少したが術後残存腫傷では, 検索したすべての血清腫瘍マーカーで有意な減少を認めなかった。化学療法で完全寛解を示した患者ではCEAを除くすべての血清腫瘍マーカーは化学療法3コース終了後有意に減少した。単一の腫瘍マーカーとしてはCA 125が最も信頼できると思われた。ついでCEA, ESR, LDH, LDH-4の順であった。しかし症例の約10%で, 治療前異常高値を示した腫傷マーカー (CA 125 or CEA) が治療後正常範囲に戻ったままで再発と共に他の腫瘍マーカーが上昇するというマーカーの解離現象が認められた。これらの成績はCA 125やCEAといったマーカーに加えていくつかのマーカーの組合せが卵巣癌の治療経過をモニターするためには必要であることを示唆している。
- 社団法人日本産科婦人科学会の論文
- 1989-01-01
著者
-
Kita Tsunekazu
Department Of Obstetrics And Gynecology National Defense Medical College
-
菊池 義公
Department of Obstetrics and Gynecology, National Defense Medical College
-
IWANO Ichiro
Department of Obstetrics and Gynecology, National Defense Medical College
-
KUKI Eiichi
Department of Obstetrics and Gynecology, National Defense Medical College
-
OOM0RI Keibun
Department of Obstetrics and Gynecology, National Defense Medical College
-
KIZAWA Isao
Department of Obstetrics and Gynecology, National Defense Medical College
-
Kizawa Isao
Department Of Obstetrics And Gynecology National Defense Medical College
-
Iwano Ichiro
Department Of Obstetrics And Gynecology National Defense Medical College
-
Oom0ri Keibun
Department Of Obstetrics And Gynecology National Defense Medical College
-
Kita Tsunekazu
Department Of Obstetrics And Gynecology Natinal Dfense Medical College
-
Kuki Eiichi
Department Of Obstetrics And Gynecology National Defense Medical College
-
Kita Tsunekazu
Department Of Obstetrics And Gynecology Nara Prefectural Nara Hospital
関連論文
- IS-36 Two cases of complete remission of metastatic and relapsed uterine cervical carcinoma using weekly administration of bevacizumab and paclitaxel/carboplatin(Group4 Oncology2,International Session)
- IS-33 Experience of combination therapy with Bevacizumab for recurrent/refractory clear cell carcinoma of the ovary(Group4 Oncology2,International Session)
- Effect of HER-2/neu overexpression on chemoresistance and prognosis in ovarian carcinoma
- Clinical significance of first-line chemotherapy and complete surgical staging for clear cell adenocarcinoma of the ovary(Oncology 3)
- PDZK1 is a potential target for 1q21-q22 amplification frequently detected in drug resistant ovarian cancer(Oncology 1)
- 4-13.CGH and cDNA micoarray analysis of drug resistance in gynecologic malignancy(Session 6 Oncology 6)
- Inhibitory Effects of Ginsenoside Rh_2 on Tumor Growth in Nude Mice Bearing Human Ovarian Cancer Cells
- Growth-inhibitory Effects of N,N-Diethyl-2-[4-(phenylmethyl)phenoxy]-ethanamine-HC1 Combined with Cisplatin on Human Ovarian Cancer Cells Inoculated into Nude Mice
- Altered Expression of γ-Glutamylcysteine Synthetase, Metallothionein and Topoisomerase I or II during Acquisition of Drug Resistance to Cisplatin in Human Ovarian Cancer Cells
- Chondrosarcomatous differentiation in metastatic deposit of serous papillary cystadenocarcinoma
- P1-IS-5 Clinical significance of immunocytochemistry for PIK3CA as a carcinogenesis-related marker on liquid-based cytology in cervical intraepithelial neoplasia
- 2-12.Clinical prospective study on post-surgical bladder dysfunction at radical hysterectomy in aspect of histological analysis of pelvic nerve innervations.(Session 3 Oncology 3)
- Characteristic expression of globotriaosyl ceramide in human ovarian carcinoma-derived cells with anticancer drug resistance
- PREDICTION OF CLINICAL COURSE AND RECURRENCE OF HUMAN OVARIAN CANCER BY SEVERAL SERUM TUMOR MARKERS
- Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary : a report of six cases
- Postoperative concurrent chemoradiotherapy for the high-risk uterine cervical cancer